{"id":"clindamycin-primaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hemolytic anemia (in G6PD-deficient patients)"},{"rate":null,"effect":"Methemoglobinemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that binds to bacterial ribosomes and inhibits protein synthesis. Primaquine is an 8-aminoquinoline that generates reactive oxygen species within protozoal parasites, disrupting their metabolism. This combination is used to treat PCP, particularly in patients who cannot tolerate trimethoprim-sulfamethoxazole.","oneSentence":"Clindamycin inhibits bacterial protein synthesis while primaquine acts as an antimalarial and antiprotozoal agent, together targeting Pneumocystis jirovecii pneumonia (PCP).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:19.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"}]},"trialDetails":[{"nctId":"NCT07357103","phase":"PHASE4","title":"Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-03","conditions":"Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection","enrollment":416},{"nctId":"NCT06691321","phase":"","title":"Caspofungin for Pneumocystis Pneumonia in PLWHIV.","status":"RECRUITING","sponsor":"Instituto Nacional de Enfermedades Respiratorias","startDate":"2023-08-01","conditions":"HIV-1-infection, Pneumocystis Pneumonia","enrollment":60},{"nctId":"NCT00000640","phase":"PHASE3","title":"A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":290},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT00636935","phase":"PHASE4","title":"Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-02","conditions":"Pneumocystis Carinii Pneumonia","enrollment":""},{"nctId":"NCT00000717","phase":"NA","title":"The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CONDITION AGGRAVATED"}],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Clindamycin + primaquine","genericName":"Clindamycin + primaquine","companyName":"McGill University Health Centre/Research Institute of the McGill University Health Centre","companyId":"mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin inhibits bacterial protein synthesis while primaquine acts as an antimalarial and antiprotozoal agent, together targeting Pneumocystis jirovecii pneumonia (PCP). Used for Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}